Hans C. de Ferrante
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hans C. de Ferrante has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Bart Smeulders
Department of Mathematics and Computer Science, Eindhoven University of Technology, Eindhoven, NETHERLANDS
2 shared publications - Frits C. R. Spieksma
Department of Mathematics and Computer Science, Eindhoven University of Technology, Eindhoven, The Netherlands
2 shared publications Ineke Tieken
Eurotransplant International Foundation (Postal Haagse Schouwweg 6 Leiden the Netherlands
2 shared publicationsS. Vogelaar
2 shared publicationsAndries E Braat
Leiden University Medical Center
1 shared publicationB. M. L. Smeulders
Department of Mathematics and Computer Science, Eindhoven University of Technology, Eindhoven, NETHERLANDS
1 shared publication
Latest Publications
- 12 November 2026
- Published by Springer Nature in Health Care Management Science
- Vol. 29 (4) , 57
The ETKidney simulator: a discrete event simulator to assess the impact of alternative kidney allocation rules in Eurotransplant
- 12 November 2026
- Published by Springer Nature in Health Care Management Science
- Vol. 29 (4) , 57
The ETKidney simulator: a discrete event simulator to assess the impact of alternative kidney allocation rules in Eurotransplant
- Open Access
- 17 February 2026
- Published by SAGE Publications in Statistical Methods in Medical Research
- Vol. 35 (4) , 812-826
Estimating conditional survival benefit for the allocation of scarce resources
Whenever treatment is scarce, the question of how to allocate resources arises. One option is to allocate based on conditional survival benefit, defined as the contrast between an individual’s expected survival with and without treatment. Estimating conditional survival benefit from observational data may present the following three challenges: (i) time-dependent confounding, arising when treatments are assigned based on longitudinal health markers which are in turn affected by past assignments; (ii) multiple time scales, namely time since becoming eligible for treatment, relevant for comparability of patients, and calendar time, representing when treatment decisions are made; and (iii) multiple versions of treatment, leading to multiple counterfactual outcomes with treatment. Building on previous work where cross-sections and inverse probability of treatment weighting were combined to estimate survival benefit on the treated population, we propose a strategy to dynamically estimate conditional survival benefit for all patients awaiting scarce treatment at any time treatment becomes available, accounting for multiple versions of treatment. After delineating identifiability assumptions, we show in a simulation study that our proposed method improves the estimation of conditional survival benefit compared to simpler methods. The proposed method is then applied to liver transplant data from the Eurotransplant region.
- 17 February 2026
- Published by SAGE Publications in Statistical Methods in Medical Research
- Vol. 35 (4) , 812-826
Open AccessEstimating conditional survival benefit for the allocation of scarce resources
Whenever treatment is scarce, the question of how to allocate resources arises. One option is to allocate based on conditional survival benefit, defined as the contrast between an individual’s expected survival with and without treatment. Estimating conditional survival benefit from observational data may present the following three challenges: (i) time-dependent confounding, arising when treatments are assigned based on longitudinal health markers which are in turn affected by past assignments; (ii) multiple time scales, namely time since becoming eligible for treatment, relevant for comparability of patients, and calendar time, representing when treatment decisions are made; and (iii) multiple versions of treatment, leading to multiple counterfactual outcomes with treatment. Building on previous work where cross-sections and inverse probability of treatment weighting were combined to estimate survival benefit on the treated population, we propose a strategy to dynamically estimate conditional survival benefit for all patients awaiting scarce treatment at any time treatment becomes available, accounting for multiple versions of treatment. After delineating identifiability assumptions, we show in a simulation study that our proposed method improves the estimation of conditional survival benefit compared to simpler methods. The proposed method is then applied to liver transplant data from the Eurotransplant region.
- Open Access
- 16 May 2025
- Published by Elsevier in Operations Research, Data Analytics and Logistics
- Vol. 45
A discrete event simulator for policy evaluation in deceased-donor liver allocation in Eurotransplant
- 16 May 2025
- Published by Elsevier in Operations Research, Data Analytics and Logistics
- Vol. 45
Open AccessA discrete event simulator for policy evaluation in deceased-donor liver allocation in Eurotransplant
- Open Access
The ETKidney simulator: a discrete event simulator to assess the impact of alternative kidney allocation rules in Eurotransplant
Over 10,000 candidates wait for a kidney transplantation in Eurotransplant, and are prioritized for transplantation based on the allocation rules of the Eurotransplant Kidney Allocation System (ETKAS) and Eurotransplant Senior Program (ESP). These allocation rules have not changed much since ETKAS and ESP's introductions in 1996 and 1999, respectively, despite identification of several areas of improvement by the Eurotransplant Kidney Advisory Committee (ETKAC). A barrier to modernizing ETKAS and ESP kidney allocation rules is that Eurotransplant lacks tools to quantitatively assess the impact of policy changes. We present the ETKidney simulator, which was developed for this purpose. This tool simulates kidney allocation according to the actual ETKAS and ESP allocation rules, and implements Eurotransplant-specific allocation mechanisms such as the system which is used to balance the international exchange of kidneys. The ETKidney simulator was developed in close collaboration with medical doctors from Eurotransplant, and was presented to ETKAC and other major stakeholders. To enhance trust in the ETKidney simulator, the simulator is made publicly available with synthetic data, and is validated by comparing simulated to actual ETKAS and ESP outcomes between 2021 and 2024. We also illustrate how the simulator can contribute to kidney policy evaluation with three clinically motivated case studies. We anticipate that the ETKidney simulator will be pivotal in modernizing ETKAS and ESP allocation rules by enabling informed decision-making on kidney allocation rules together with national competent authorities.
Open AccessThe ETKidney simulator: a discrete event simulator to assess the impact of alternative kidney allocation rules in Eurotransplant
Over 10,000 candidates wait for a kidney transplantation in Eurotransplant, and are prioritized for transplantation based on the allocation rules of the Eurotransplant Kidney Allocation System (ETKAS) and Eurotransplant Senior Program (ESP). These allocation rules have not changed much since ETKAS and ESP's introductions in 1996 and 1999, respectively, despite identification of several areas of improvement by the Eurotransplant Kidney Advisory Committee (ETKAC). A barrier to modernizing ETKAS and ESP kidney allocation rules is that Eurotransplant lacks tools to quantitatively assess the impact of policy changes. We present the ETKidney simulator, which was developed for this purpose. This tool simulates kidney allocation according to the actual ETKAS and ESP allocation rules, and implements Eurotransplant-specific allocation mechanisms such as the system which is used to balance the international exchange of kidneys. The ETKidney simulator was developed in close collaboration with medical doctors from Eurotransplant, and was presented to ETKAC and other major stakeholders. To enhance trust in the ETKidney simulator, the simulator is made publicly available with synthetic data, and is validated by comparing simulated to actual ETKAS and ESP outcomes between 2021 and 2024. We also illustrate how the simulator can contribute to kidney policy evaluation with three clinically motivated case studies. We anticipate that the ETKidney simulator will be pivotal in modernizing ETKAS and ESP allocation rules by enabling informed decision-making on kidney allocation rules together with national competent authorities.
- Open Access
- 9 July 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (1) , 139-149
Sex disparity in liver allocation within Eurotransplant
- 9 July 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (1) , 139-149
Open AccessSex disparity in liver allocation within Eurotransplant
- Open Access
- 28 February 2024
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 24 (1) , 1-10
Revising model for end-stage liver disease from calendar-time cross-sections with correction for selection bias
Eurotransplant liver transplant candidates are prioritized by Model for End-stage Liver Disease (MELD), a 90-day waitlist survival risk score based on the INR, creatinine and bilirubin. Several studies revised the original MELD score, UNOS-MELD, with transplant candidate data by modelling 90-day waitlist mortality from waitlist registration, censoring patients at delisting or transplantation. This approach ignores biomarkers reported after registration, and ignores informative censoring by transplantation and delisting. We study how MELD revision is affected by revision from calendar-time cross-sections and correction for informative censoring with inverse probability censoring weighting (IPCW). For this, we revised UNOS-MELD on patients with chronic liver cirrhosis on the Eurotransplant waitlist between 2007 and 2019 (n = 13,274) with Cox models with as endpoints 90-day survival (a) from registration and (b) from weekly drawn calendar-time cross-sections. We refer to the revised score from cross-section with IPCW as DynReMELD, and compare DynReMELD to UNOS-MELD and ReMELD, a prior revision of UNOS-MELD for Eurotransplant, in geographical validation. Revising MELD from calendar-time cross-sections leads to significantly different MELD coefficients. IPCW increases estimates of absolute 90-day waitlist mortality risks by approximately 10 percentage points. DynReMELD has improved discrimination over UNOS-MELD (delta c-index: 0.0040, p < 0.001) and ReMELD (delta c-index: 0.0015, p < 0.01), with differences comparable in magnitude to the addition of an extra biomarker to MELD (delta c-index: ± 0.0030). Correcting for selection bias by transplantation/delisting does not improve discrimination of revised MELD scores, but substantially increases estimated absolute 90-day mortality risks. Revision from cross-section uses waitlist data more efficiently, and improves discrimination compared to revision of MELD exclusively based on information available at listing.
- 28 February 2024
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 24 (1) , 1-10
Open AccessRevising model for end-stage liver disease from calendar-time cross-sections with correction for selection bias
Eurotransplant liver transplant candidates are prioritized by Model for End-stage Liver Disease (MELD), a 90-day waitlist survival risk score based on the INR, creatinine and bilirubin. Several studies revised the original MELD score, UNOS-MELD, with transplant candidate data by modelling 90-day waitlist mortality from waitlist registration, censoring patients at delisting or transplantation. This approach ignores biomarkers reported after registration, and ignores informative censoring by transplantation and delisting. We study how MELD revision is affected by revision from calendar-time cross-sections and correction for informative censoring with inverse probability censoring weighting (IPCW). For this, we revised UNOS-MELD on patients with chronic liver cirrhosis on the Eurotransplant waitlist between 2007 and 2019 (n = 13,274) with Cox models with as endpoints 90-day survival (a) from registration and (b) from weekly drawn calendar-time cross-sections. We refer to the revised score from cross-section with IPCW as DynReMELD, and compare DynReMELD to UNOS-MELD and ReMELD, a prior revision of UNOS-MELD for Eurotransplant, in geographical validation. Revising MELD from calendar-time cross-sections leads to significantly different MELD coefficients. IPCW increases estimates of absolute 90-day waitlist mortality risks by approximately 10 percentage points. DynReMELD has improved discrimination over UNOS-MELD (delta c-index: 0.0040, p < 0.001) and ReMELD (delta c-index: 0.0015, p < 0.01), with differences comparable in magnitude to the addition of an extra biomarker to MELD (delta c-index: ± 0.0030). Correcting for selection bias by transplantation/delisting does not improve discrimination of revised MELD scores, but substantially increases estimated absolute 90-day mortality risks. Revision from cross-section uses waitlist data more efficiently, and improves discrimination compared to revision of MELD exclusively based on information available at listing.
- 25 September 2023
- Published by Wolters Kluwer Health in Transplantation
- Vol. 107 (10) , 2247-2254
Immunized Patients Face Reduced Access to Transplantation in the Eurotransplant Kidney Allocation System
Background.: The presence of donor-specific HLA antibodies before transplantation is associated with poor transplantation outcomes. Unacceptable antigens can be assigned for Eurotransplant kidney transplant candidates to prevent kidney offers against which the candidate has developed clinically relevant HLA antibodies. This retrospective cohort study aimed to assess to what degree unacceptable antigens affect access to transplantation in the Eurotransplant Kidney Allocation System (ETKAS). Methods.: Candidates who underwent kidney-only transplantation between 2016 and 2020 were included (n = 19 240). Cox regression was used to quantify the relationship between the relative transplantation rate and virtual panel-reactive antibodies (vPRAs), which is the percentage of the donor pool with unacceptable antigens. Models used accrued dialysis time as the timescale; were stratified by country and blood group of patient and were adjusted for nontransplantable status, patient age, sex, history of kidney transplantations, and prevalence of 0 HLA-DR–mismatched donors. Results.: Transplantation rates were 23% lower for vPRA 0.1% to 50%, 51% lower for vPRA 75% to 85%, and decreased rapidly for vPRA of >85%. Prior studies showed significantly lower ETKAS transplantation rates only for highly sensitized patients (vPRA of >85%). The inverse relationship between transplantation rate and vPRA is independent of Eurotransplant country, listing time, and 0 HLA-DR–mismatched donor availability. Results were similar when quantifying the relationship between vPRA and attainment of a sufficiently high rank for an ETKAS offer, suggesting lower transplantation rates for immunized patients are due to current ETKAS allocation. Conclusions.: Immunized patients face lower transplantation rates across Eurotransplant. The current ETKAS allocation mechanism inadequately compensates immunized patients for reduced access to transplantation.
- 25 September 2023
- Published by Wolters Kluwer Health in Transplantation
- Vol. 107 (10) , 2247-2254
Immunized Patients Face Reduced Access to Transplantation in the Eurotransplant Kidney Allocation System
Background.: The presence of donor-specific HLA antibodies before transplantation is associated with poor transplantation outcomes. Unacceptable antigens can be assigned for Eurotransplant kidney transplant candidates to prevent kidney offers against which the candidate has developed clinically relevant HLA antibodies. This retrospective cohort study aimed to assess to what degree unacceptable antigens affect access to transplantation in the Eurotransplant Kidney Allocation System (ETKAS). Methods.: Candidates who underwent kidney-only transplantation between 2016 and 2020 were included (n = 19 240). Cox regression was used to quantify the relationship between the relative transplantation rate and virtual panel-reactive antibodies (vPRAs), which is the percentage of the donor pool with unacceptable antigens. Models used accrued dialysis time as the timescale; were stratified by country and blood group of patient and were adjusted for nontransplantable status, patient age, sex, history of kidney transplantations, and prevalence of 0 HLA-DR–mismatched donors. Results.: Transplantation rates were 23% lower for vPRA 0.1% to 50%, 51% lower for vPRA 75% to 85%, and decreased rapidly for vPRA of >85%. Prior studies showed significantly lower ETKAS transplantation rates only for highly sensitized patients (vPRA of >85%). The inverse relationship between transplantation rate and vPRA is independent of Eurotransplant country, listing time, and 0 HLA-DR–mismatched donor availability. Results were similar when quantifying the relationship between vPRA and attainment of a sufficiently high rank for an ETKAS offer, suggesting lower transplantation rates for immunized patients are due to current ETKAS allocation. Conclusions.: Immunized patients face lower transplantation rates across Eurotransplant. The current ETKAS allocation mechanism inadequately compensates immunized patients for reduced access to transplantation.
- Open Access
PIPENN: Protein Interface Prediction with an Ensemble of Neural Nets
Motivation Protein interactions play an essential role in many biological and cellular processes, such as protein–protein interaction (PPI) in signaling pathways, binding to DNA in transcription, and binding to small molecules in receptor activation or enzymatic activity. Experimental identification of protein binding interface residues is a time-consuming, costly, and challenging task. Several machine learning and other computational approaches exist which predict such interface residues. Here we explore if Deep Learning (DL) can be used effectively for this prediction task, and which learning strategies and architectures may be most efficient. We introduce seven DL architectures that are applied to eleven independent test sets, focused on the residues involved in PPI interfaces and in binding RNA/DNA and small molecule ligands. Results We constructed a large data set dubbed BioDL, comprising protein-protein interaction data from the PDB and protein-ligand interactions (DNA, RNA and small molecules) from the BioLip database. Additionally, we reused our existing curated homo- and heteromeric PPI data sets. We performed several experiments to assess the impact of different data features, spatial forms, encoding schemes, network initializations, loss functions, regularization mechanisms, and activation functions on the performance of the predictors. Benchmarking the resulting DL models with an independent test set (ZK448) shows no single DL architecture performs best on all instances, but that an ensemble of DL architectures consistently achieves peak prediction performance. Our PIPENN’s ensemble predictor outperforms current state-of-the-art sequence-based protein interface predictors on all interaction types, achieving AUCs of 0.718 (protein–protein), 0.823 (protein–nucleotide) and 0.842 (protein– small molecule) respectively. Availability Source code and data sets at https://github.com/ibivu/pipenn/ Contact r.haydarlou{at}vu.nl
Open AccessPIPENN: Protein Interface Prediction with an Ensemble of Neural Nets
Motivation Protein interactions play an essential role in many biological and cellular processes, such as protein–protein interaction (PPI) in signaling pathways, binding to DNA in transcription, and binding to small molecules in receptor activation or enzymatic activity. Experimental identification of protein binding interface residues is a time-consuming, costly, and challenging task. Several machine learning and other computational approaches exist which predict such interface residues. Here we explore if Deep Learning (DL) can be used effectively for this prediction task, and which learning strategies and architectures may be most efficient. We introduce seven DL architectures that are applied to eleven independent test sets, focused on the residues involved in PPI interfaces and in binding RNA/DNA and small molecule ligands. Results We constructed a large data set dubbed BioDL, comprising protein-protein interaction data from the PDB and protein-ligand interactions (DNA, RNA and small molecules) from the BioLip database. Additionally, we reused our existing curated homo- and heteromeric PPI data sets. We performed several experiments to assess the impact of different data features, spatial forms, encoding schemes, network initializations, loss functions, regularization mechanisms, and activation functions on the performance of the predictors. Benchmarking the resulting DL models with an independent test set (ZK448) shows no single DL architecture performs best on all instances, but that an ensemble of DL architectures consistently achieves peak prediction performance. Our PIPENN’s ensemble predictor outperforms current state-of-the-art sequence-based protein interface predictors on all interaction types, achieving AUCs of 0.718 (protein–protein), 0.823 (protein–nucleotide) and 0.842 (protein– small molecule) respectively. Availability Source code and data sets at https://github.com/ibivu/pipenn/ Contact r.haydarlou{at}vu.nl